Publications by authors named "John Crown"

100Publications

The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.

Invest New Drugs 2020 Oct 14. Epub 2020 Oct 14.

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-01018-wDOI Listing
October 2020

Targeting p53 for the treatment of cancer.

Semin Cancer Biol 2020 Jul 30. Epub 2020 Jul 30.

Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2020.07.005DOI Listing
July 2020

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer.

Br J Cancer 2020 Oct 27;123(8):1219-1222. Epub 2020 Jul 27.

National Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0999-zDOI Listing
October 2020

Drugging "undruggable" genes for cancer treatment: Are we making progress?

Int J Cancer 2020 Jul 7. Epub 2020 Jul 7.

Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.33197DOI Listing
July 2020

Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.

Semin Cancer Biol 2020 Jul 2. Epub 2020 Jul 2.

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2020.06.016DOI Listing
July 2020

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

J Clin Oncol 2020 Sep 2;38(25):2883-2891. Epub 2020 Jul 2.

Unit of Medical Statistics, Biometry and Bioinformatics Giulio A. Maccacaro Department of Clinical Sciences and Community Health & DSRC, University of Milan, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01771DOI Listing
September 2020

Metastatic uveal melanoma: A valid indication for liver resection.

J BUON 2020 Mar-Apr;25(2):1161-1165

Department of Hepatobiliary and Liver Transplant Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
June 2020

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.

Invest New Drugs 2020 Oct 22;38(5):1365-1372. Epub 2020 Apr 22.

Molecular Therapeutics for Cancer in Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00937-yDOI Listing
October 2020

Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.

Sci Rep 2020 02 17;10(1):2778. Epub 2020 Feb 17.

National Institute for Cellular Biotechnology, School of Biotechnology, Dublin City University, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-59368-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026166PMC
February 2020

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.

Breast Cancer Res Treat 2020 Jan 19;179(1):47-56. Epub 2019 Sep 19.

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05435-1DOI Listing
January 2020

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.

Clin Chem 2019 10 17;65(10):1228-1238. Epub 2019 Jul 17.

Medical Oncology Department, St. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2019.303644DOI Listing
October 2019

Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.

Sci Rep 2019 06 24;9(1):9204. Epub 2019 Jun 24.

Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-45444-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591410PMC
June 2019

First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.

Am J Med Genet A 2019 07 6;179(7):1319-1324. Epub 2019 May 6.

Center for Rare Diseases and Birth Defects, Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.61160DOI Listing
July 2019

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Cancers (Basel) 2019 Apr 17;11(4). Epub 2019 Apr 17.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin D09 NR58, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520724PMC
April 2019

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.

Cancers (Basel) 2019 Feb 8;11(2). Epub 2019 Feb 8.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, 9 Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406301PMC
February 2019

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med 2019 02 5;380(7):617-628. Epub 2018 Dec 5.

From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814017
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814017DOI Listing
February 2019

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.

Transl Oncol 2018 Dec 6;11(6):1343-1349. Epub 2018 Sep 6.

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2018.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132178PMC
December 2018

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Invest New Drugs 2019 06 30;37(3):441-451. Epub 2018 Jul 30.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0649-yDOI Listing
June 2019

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.

Tumour Biol 2018 May;40(5):1010428318776169

2 UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428318776169DOI Listing
May 2018

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.

Breast Cancer Res Treat 2018 Jul 21;170(2):213-219. Epub 2018 Mar 21.

Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4753-7DOI Listing
July 2018

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

Int J Radiat Oncol Biol Phys 2018 06 6;101(2):316-324. Epub 2018 Feb 6.

International Breast Cancer Study Group, Bern, Switzerland; Peter MacCallum Cancer Centre, Melbourne, Australia; St. Vincents's Hospital, University of Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Newcastle, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.01.105DOI Listing
June 2018

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Invest New Drugs 2018 08 2;36(4):581-589. Epub 2018 Feb 2.

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0556-7DOI Listing
August 2018

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.

Oncoimmunology 2017 11;6(12):e1362530. Epub 2017 Aug 11.

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1362530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706614PMC
August 2017

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?

Cureus 2017 Sep 5;9(9):e1654. Epub 2017 Sep 5.

Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.1654DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669532PMC
September 2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Cancer Lett 2018 02 22;414:99-106. Epub 2017 Oct 22.

UCD School of Medicine, University College Dublin, Dublin 4, Ireland; UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin 4, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.09.053DOI Listing
February 2018

Mutant p53 as a target for cancer treatment.

Eur J Cancer 2017 09 28;83:258-265. Epub 2017 Jul 28.

Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.06.023DOI Listing
September 2017

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Cell Immunol 2017 Sep 15;319:35-42. Epub 2017 Jul 15.

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland; Department of Medical Oncology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00088749173011
Publisher Site
http://dx.doi.org/10.1016/j.cellimm.2017.07.005DOI Listing
September 2017

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.

Int J Oncol 2017 Jun 26;50(6):2221-2228. Epub 2017 Apr 26.

National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2017.3976DOI Listing
June 2017

Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.

Int J Cancer 2017 06;140(12):2771-2784

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.30705
Publisher Site
http://dx.doi.org/10.1002/ijc.30705DOI Listing
June 2017

Vitamin D analogues: Potential use in cancer treatment.

Crit Rev Oncol Hematol 2017 Apr 22;112:190-197. Epub 2017 Feb 22.

Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.02.015DOI Listing
April 2017

Vitamin D receptor as a target for breast cancer therapy.

Endocr Relat Cancer 2017 04 17;24(4):181-195. Epub 2017 Feb 17.

UCD School of MedicineConway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-16-0463DOI Listing
April 2017

CDK8: a new breast cancer target.

Authors:
John Crown

Oncotarget 2017 02;8(9):14269-14270

Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362398PMC
February 2017

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.

Clin Chem 2017 04 10;63(4):804-806. Epub 2017 Feb 10.

Medical Oncology Department, St. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2016.267161DOI Listing
April 2017

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

J Clin Oncol 2016 10;34(29):3518-3528

Michael F. Press, Denice D. Tsao-Wei, Yanling Ma, Ivonne Villalobos, and Anaamika Campeau, University of Southern California Norris Comprehensive Cancer Center; Dennis J. Slamon, Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA; Nicholas Robert, Virginia Cancer Specialists/US Oncology Research Network, Fairfax, VA; Vicente Valero, The University of Texas MD Anderson Cancer Center, Houston, TX; Guido Sauter and Martina Mirlacher, University of Hamburg, Hamburg; Wolfgang Eiermann, Frauenklinik vom Roten Kreuz, Munich, Germany; Marc Buyse, Hélène Fourmanoir, and Emmanuel Quinaux, International Drug Development Institute, Louvain-la-Neuve, Belgium; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; John Crown, Irish Cooperative Onoclogy Research Group, St Vincent's University Hospital, Dublin, Ireland; Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain; John R. Mackey, University of Alberta; Mary-Ann Lindsay, Cancer International Research Group/Translational Research in Oncology, Edmonton, Alberta, Canada; and Valerie Bee, Cancer International Research Group/Translational Research in Oncology, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.6693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074347PMC
October 2016

Validated biomarkers: The key to precision treatment in patients with breast cancer.

Breast 2016 Oct 9;29:192-201. Epub 2016 Aug 9.

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; Medical Oncology Department, St Vincent's University Hospital, Dublin 4, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.07.009DOI Listing
October 2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

J Natl Cancer Inst 2016 08 4;108(8). Epub 2016 Jul 4.

Medical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017949PMC
August 2016

The ADAMs family of proteases as targets for the treatment of cancer.

Cancer Biol Ther 2016 08 26;17(8):870-80. Epub 2016 Apr 26.

b UCD School of Medicine and Medical Science , Conway Institute of Biomolecular and Biomedical Research, University College Dublin , Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2016.1177684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004698PMC
August 2016

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Endocr Relat Cancer 2016 Apr 1;23(4):323-34. Epub 2016 Mar 1.

School of MedicineUniversity College Dublin, Ireland UCD Clinical Research CentreSt. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
https://erc.bioscientifica.com/view/journals/erc/23/4/323.xm
Publisher Site
http://dx.doi.org/10.1530/ERC-16-0068DOI Listing
April 2016

Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients.

BBA Clin 2014 Dec 16;2:24-30. Epub 2014 Sep 16.

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbacli.2014.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633920PMC
December 2014

Biomarkers in Breast Cancer: Where Are We and Where Are We Going?

Adv Clin Chem 2015 23;71:1-23. Epub 2015 Jun 23.

Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acc.2015.05.001DOI Listing
April 2016

ADAM10: a new player in breast cancer progression?

Br J Cancer 2015 Sep 18;113(6):945-51. Epub 2015 Aug 18.

UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578086PMC
September 2015

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

Melanoma Res 2015 Jun;25(3):189-99

aOncoMark Ltd, NovaUCD bDepartment of Medical Oncology, Royal College of Surgeons cUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin Departments of dPathology eSurgery fMedical Oncology, St Vincent's University Hospital gDepartment of Histopathology, Royal College of Surgeons in Ireland Education and Research Centre, Beaumont Hospital hDepartment of Histopathology, St James's Hospital iDepartment of Histopathology, Trinity College, Dublin jDepartment of Pathology, Cork University Hospital, Cork Departments of kSurgery lMedical Oncology, University Hospital Galway mDepartment of Medicine, National University of Ireland Galway nDepartment of Histopathology, University Hospital Galway, Galway, Ireland oDepartment of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands pLaboratory of Morphology and Molecular Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000149DOI Listing
June 2015

Predictive biomarkers for dasatinib treatment in melanoma.

Oncoscience 2014 12;1(2):158-66. Epub 2014 Mar 12.

National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278284PMC
http://dx.doi.org/10.18632/oncoscience.20DOI Listing
January 2015

ADAM10 and ADAM17: New players in trastuzumab tesistance.

Oncotarget 2014 Nov;5(22):10963-4

Education and Research Centre, St. Vincent's University Hospital, Dublin and UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294375PMC
http://dx.doi.org/10.18632/oncotarget.2794DOI Listing
November 2014

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Mol Cancer 2014 Oct 24;13:241. Epub 2014 Oct 24.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219121PMC
October 2014

Monitoring response to therapy in patients with cancer: is circulating DNA the answer?

Ann Transl Med 2013 Oct;1(3):24

1 UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland ; 2 Clinical Research Centre, 3 Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2013.07.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200673PMC
October 2013

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Expert Opin Ther Targets 2014 Sep 1;18(9):999-1009. Epub 2014 Aug 1.

Dublin City University, National Institute for Cellular Biotechnology , Dublin 9 , Ireland +00353 1 7007497 ; +00353 1 7005484 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2014.938050DOI Listing
September 2014

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Mol Cancer 2014 Jun 24;13:157. Epub 2014 Jun 24.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230643PMC
June 2014

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.

Mol Cancer 2014 Mar 24;13:71. Epub 2014 Mar 24.

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-71DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234346PMC
March 2014

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.

Front Oncol 2014 6;4:40. Epub 2014 Mar 6.

National Institute for Cellular Biotechnology, Dublin City University , Dublin , Ireland ; Department of Histopathology, St James' Hospital, Trinity College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fonc.2014.000
Publisher Site
http://dx.doi.org/10.3389/fonc.2014.00040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944788PMC
March 2014

Precision treatment for cancer: role of prognostic and predictive markers.

Crit Rev Clin Lab Sci 2014 Feb 16;51(1):30-45. Epub 2014 Jan 16.

Clinical Research Centre .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10408363.2013.865700DOI Listing
February 2014

Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.

Acta Oncol 2014 Feb 14;53(2):201-8. Epub 2013 Oct 14.

School of Economics and Geary Institute, University College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/0284186X.2013.840740DOI Listing
February 2014

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.

Cancer Biol Ther 2013 Dec 4;14(12):1104-12. Epub 2013 Sep 4.

School of Pharmacy & Pharmaceutical Sciences and Trinity Biomedical Sciences Institute; Trinity College Dublin; Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.26370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912033PMC
December 2013

A gene expression profile indicative of early stage HER2 targeted therapy response.

Mol Cancer 2013 Jul 1;12:69. Epub 2013 Jul 1.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-12-69DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725168PMC
July 2013

Companion biomarkers: paving the pathway to personalized treatment for cancer.

Clin Chem 2013 Oct 8;59(10):1447-56. Epub 2013 May 8.

UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Ireland;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2012.200477DOI Listing
October 2013

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.

Eur J Cancer 2013 May 27;49(8):1845-59. Epub 2013 Feb 27.

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.01.017DOI Listing
May 2013

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.

Breast Cancer Res Treat 2012 Dec 2;136(3):717-27. Epub 2012 Nov 2.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2260-9
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2260-9DOI Listing
December 2012

EGFR and HER2 inhibition in pancreatic cancer.

Invest New Drugs 2013 Jun 18;31(3):558-66. Epub 2012 Oct 18.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9891-xDOI Listing
June 2013

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

Mol Cancer 2012 Jun 18;11:41. Epub 2012 Jun 18.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-11-41DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439312PMC
June 2012

Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.

J Clin Oncol 2012 Sep 29;30(26):e257-9. Epub 2012 May 29.

St Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.8942DOI Listing
September 2012